Introduction
Invivyd, Inc. (Nasdaq: IVVD) – formerly Adagio Therapeutics – is a biotech focused on antibody therapies for infectious diseases. The company recently achieved a key milestone: the FDA granted Fast Track designation to its next-generation COVID-19 antibody VYD2311 for prevention of COVID-19 in high-risk individuals ([1]). This status can expedite development and review, potentially allowing priority review and rolling submissions if criteria are met ([1]). Management emphasizes the urgent need for new prophylactic options as COVID-19 becomes endemic ([1]). Invivyd has already initiated DECLARATION, a pivotal Phase 3 trial of VYD2311, with top-line data expected by mid-2026 ([1]). Investors have taken notice – the stock has rallied sharply on growing optimism around VYD2311’s prospects.
Company Overview & Recent Developments
Invivyd was born from the struggles of its predecessor Adagio, which saw its lead antibody falter against Omicron variants. In 2022 the company rebranded to Invivyd and refocused its platform on rapidly evolving antiviral antibodies ([2]) ([3]). Its first product, PEMGARDA™ (pemivibart), is a long-acting monoclonal antibody derived from Adagio’s original ADG20 candidate. PEMGARDA secured U.S. Emergency Use Authorization (EUA) in March 2024 for pre-exposure prophylaxis of COVID-19 in immunocompromised patients ([4]) ([4]). This made Invivyd one of the only options for those who can’t mount vaccine immunity.
Commercial progress: Since EUA, PEMGARDA has generated growing revenue. Full-year 2024 net product revenue was $25.4 million ([5]) – mostly in the second half after launch – and Q1 2025 alone brought in $11.3 million ([6]). By Q3 2025, quarterly revenue reached $13.1 million, up 41% year-over-year ([7]), as the company’s in-house sales force expanded outreach to oncology and transplant centers. Invivyd had aimed to achieve profitability by mid-2025; while this goal slipped, revenue continues to grow and net losses have narrowed significantly (Q3 2025 net loss was $10.5M, improved from $60.7M a year prior) ([7]). The FDA Fast Track news in Dec 2025 further validates Invivyd’s pipeline – VYD2311 is a next-gen antibody engineered via serial molecular evolution to neutralize current variants and allow intramuscular dosing for potentially long-lasting protection ([4]) ([4]). With IND cleared and alignment on a pivotal trial program (including the DECLARATION study for efficacy and a LIBERTY sub-trial for use alongside vaccines) ([8]), VYD2311 is on track to enter Phase 2/3 around year-end 2025. Success could position Invivyd as a leader in preventive COVID-19 therapeutics.
Dividend Policy & Shareholder Return
Dividends: Invivyd is a clinical-stage growth company and does not pay dividends – nor does it anticipate paying any in the foreseeable future ([9]). The company has never declared a cash dividend and intends to reinvest all earnings into R&D and commercialization. Investors should not expect income returns; as the 10-K cautions, any shareholder gains will likely come solely from stock price appreciation ([9]). This policy is typical for biotech firms, reflecting the priority on funding drug development over returning cash to shareholders. The dividend yield on IVVD is therefore 0%, and management has indicated no plans to initiate dividends until sustained profitability is achieved. Instead, Invivyd’s capital strategy has focused on equity financing (and recently a term loan facility – see below) to support its pipeline.
Nearly 100 — core advantage for robotics integration
Tiger, Sequoia, Fidelity, Amazon, Tesla investments
Share buybacks: Likewise, Invivyd has not engaged in stock repurchases. All available capital is being directed toward advancing clinical programs and building out commercialization capabilities. For now, shareholders are betting on growth: the company’s value proposition is tied to successful product development and market adoption, not near-term yield.
Financials, Cash Flow & Leverage
Revenue and profitability: Invivyd’s financial profile is evolving from a pure R&D outfit toward a commercial-stage biotech. The launch of PEMGARDA under EUA in 2024 introduced the company’s first revenues. After $25.4M in sales for full-year 2024 ([5]), the run-rate accelerated in 2025 – first-half 2025 revenue was $23.1M (Q1 $11.3M, Q2 $11.8M) ([6]) ([4]), and Q3 added another $13.1M ([7]). This trajectory put trailing 12-month revenue around $50 million by Q3 2025. Importantly, Invivyd has been reducing its cash burn through cost cuts and efficiency: Q3 2025 R&D expense was just $8.0M, down sharply from $57.9M in Q3 2024, due to lower manufacturing/trial costs post-launch ([7]). SG&A was $15.0M for the quarter, roughly flat year-over-year ([7]) despite supporting a new salesforce. As a result, quarterly net loss shrank to $10.5M (or $0.06 per share) in Q3 2025 ([7]). Invivyd did not meet its goal of breaking even by mid-2025, but management still sees a path to profitability with continued revenue growth in the respiratory virus season ([4]). Investors should watch upcoming quarters to see if higher COVID infection rates translate into enough PEMGARDA uptake to push Invivyd into the black. The company’s gross margin profile isn’t explicitly broken out, but given PEMGARDA’s biologic manufacturing costs, margins are likely moderate. However, with much of the heavy R&D spend behind and streamlined operations, incremental revenue can significantly improve the bottom line.
Cash position: Biotechs live or die by their cash runway, and Invivyd has been proactive in shoring up its balance sheet. As of September 30, 2025, the company held $85.0 million in cash and cash equivalents ([8]). This reflected a major boost from financing activities: Invivyd closed a $57.5M equity offering in August 2025 and raised an additional $29.8M via its at-the-market (ATM) facility in October ([8]). These infusions lifted cash from $34.9M in June 2025 ([4]) to over $100M by the end of October ([8]). Subsequent events: In November 2025, leveraging positive news momentum, Invivyd executed a much larger capital raise – a $125 million public offering – selling 44 million shares at $2.50 each (plus 6 million pre-funded warrants at $2.4999) ([10]). This significantly strengthens the balance sheet. Pro forma for the November deal, year-end 2025 cash likely exceeds $200 million. Such a cash war chest should fund the company through its Phase 3 trial readouts and potential BLA filing for VYD2311 in 2026, as well as early pipeline efforts in RSV and measles. It’s worth noting these equity raises have been dilutive (total shares outstanding roughly tripled in 2025), but Invivyd was able to raise needed capital at progressively higher prices – from $0.52 in the August offering ([11]) to $2.50 in November ([10]) – indicating growing investor confidence.
Leverage and maturities: Invivyd carries minimal debt. In April 2025, the company arranged a $30 million term loan facility with Silicon Valley Bank (SVB) to provide “non-dilutive” funding flexibility ([12]). However, this facility is undrawn to date – likely because equity financing covered near-term needs, and the loan tranches are only available upon hitting certain milestones. Under the SVB Loan Agreement, the $30M is split into three $10M tranches: Term A (available Aug 15, 2025 onward, contingent on meeting financial covenants), and Term B/C (tied to achieving product revenue milestones, available into 2027) ([13]). Any borrowed amounts will mature on March 1, 2029 ([13]). The interest rate is floating with a 6.00% floor (capped at ~9% if prime rises) ([13]), and the loan is interest-only until at least April 2027. In effect, this facility serves as a backstop – giving Invivyd optional liquidity if needed for commercialization or if markets tighten. As of Q3 2025, no debt was on the balance sheet (aside from ordinary course liabilities), and lease obligations are modest (leases on office/lab space run into 2026) ([9]). The loan’s covenants restrict typical activities (incurring more debt, paying dividends, etc.) ([13]) ([13]), but with no borrowings yet, these haven’t come into play. Invivyd’s interest coverage is not meaningful at this stage given negative earnings and no interest expense. The company is effectively equity-funded, which reduces financial risk – though it dilutes shareholders, as seen with 2025’s offerings. The upside is a fortified runway: management believes current cash (and available debt if tapped) can support operations at least through the mid-2026 Phase 3 results and possibly into a commercial launch. Investors should monitor cash burn and sales uptake to gauge if additional financing might be needed; for now, Invivyd appears well-capitalized for its next milestones.
Valuation & Comparative Metrics
Valuing a clinical-stage biotech like Invivyd is challenging – traditional multiples are of limited use while the company is not yet profitable. However, Invivyd’s emerging revenue stream and substantial pipeline progress allow some benchmarks:
– Market capitalization: After the late-2025 equity raises, Invivyd has approximately 180–200 million shares outstanding (including exercised pre-funded warrants and new shares). At a recent share price around ~$2.50–2.70, the market cap sits roughly in the $450–500 million range. Backing out the hefty cash reserves (~$200M+ post-November offering), the enterprise value (EV) is on the order of $250–300 million.
– Revenue multiples: Trailing 12-month product revenue is about $50 million (Q4’24–Q3’25 sum) ([7]) ([5]). This implies EV/revenue of ~5–6×. On a forward basis, if PEMGARDA sales continue growing (and assuming EUA remains in effect), 2025–26 revenues could be higher. Even so, Invivyd’s valuation primarily hinges on expectations for VYD2311 and beyond, rather than the small existing revenue base. For context, AstraZeneca’s Evusheld (a similar COVID antibody for prophylaxis) generated $556 million in U.S. sales in the first half of 2022 ([14]) before variant resistance ended its run. Invivyd’s current ~$0.5B valuation reflects a market view that VYD2311 could tap into a meaningful niche (potentially hundreds of millions in annual sales in a favorable scenario), but also prices in the risks of development and competition.
– Peer comparison: Another comparable is Vir Biotechnology (VIR) – a biotech that had success with a COVID antibody (sotrovimab with GSK) and is pivoting to other infectious diseases. Vir, which is further along with multiple programs, traded around a $900 million market cap in late 2025 ([15]), despite having over $1 billion in 2021 COVID revenue that has since waned. Vir’s stock fell over 80% from pandemic highs as its antibody lost effectiveness, illustrating the volatility in this space ([16]). Compared to Vir, Invivyd is smaller but more singularly focused on COVID prophylaxis. Notably, Invivyd’s ~$250M EV is supported by its cash on hand and EUA product, essentially valuing the pipeline (VYD2311 and early RSV/measles candidates) at only a couple hundred million. If VYD2311 achieves FDA approval and significant uptake, that valuation could prove low. On the other hand, setbacks could make even the current valuation look rich. Biotech investors often value such companies on probability-adjusted NPV of future cash flows or by comparing to similar licensing deals. In Invivyd’s case, the lack of directly comparable approved prophylactic antibodies makes it a unique story. The price-to-book is also worth noting: with ~$200M cash and negligible debt, IVVD’s P/B is close to 2×, indicating the market is assigning substantial value to intangible assets (IP and trial data).
– P/FFO or P/E: Traditional earnings multiples are not meaningful for Invivyd yet, as it still posts net losses (–$0.06 EPS in Q3 2025 ([7])). Analysts instead will look at metrics like cash burn (about $10–15M per quarter recently) versus cash reserves, and the potential ROI on R&D spending if VYD2311 is approved. If Invivyd can reach its goal of profitability in the near future, we may start to evaluate it on a P/E or EV/EBITDA basis, but until then it trades on clinical momentum and sales growth of PEMGARDA.
In summary, Invivyd’s valuation suggests the market is cautiously optimistic – assigning a few hundred million dollars of value to its platform and prospects. This leaves substantial upside if VYD2311 becomes a multi-year revenue generator (for example, a successful prophylactic antibody could command premium pricing and government contracts, as Evusheld did with a $855M U.S. supply deal ([14])). Conversely, the valuation would likely compress if trial results disappoint or if COVID prophylaxis demand fades. Investors “don’t want to miss out” on what could be a lucrative niche, but they are also mindful of the binary risks inherent in drug development.
Risks and Red Flags
Despite its promising developments, Invivyd faces numerous risks and challenges that investors should weigh:
– Regulatory & Variant Risk: Invivyd’s current product PEMGARDA is only authorized under EUA, which can be revoked at any time. In fact, authorization is conditional on variant susceptibility – if resistant strains (against which pemivibart has “substantially reduced” activity) exceed 90% of circulating viruses nationally, PEMGARDA would no longer be allowed ([17]). This is exactly what happened to AstraZeneca’s Evusheld, which lost U.S. authorization in early 2023 when new Omicron subvariants emerged ([18]). Invivyd’s strategy relies on staying ahead of the virus: VYD2311 is designed for current variants, but SARS-CoV-2 could mutate further, potentially undermining efficacy by the time of approval. The company will need to continually monitor viral evolution – and possibly develop successive antibodies – to remain relevant. This “cat-and-mouse” dynamic means revenues could be temporary or volatile. The FDA’s Fast Track designation, while positive, is not a guarantee of approval. Invivyd must still demonstrate robust Phase 3 efficacy in preventing COVID-19. If the DECLARATION trial fails to show a statistically significant risk reduction (or if safety issues arise), VYD2311’s pathway could be derailed. In short, clinical and regulatory outcomes remain uncertain, as the company itself acknowledges in its forward-looking statements ([4]) ([4]).
– Market Adoption & Competition: Even if Invivyd successfully brings VYD2311 to market, it faces the question of demand. The target populations – immunocompromised patients and possibly broader groups seeking extra protection – may be limited and hard to penetrate. During COVID’s emergency phase, government purchases drove antibody usage. In a post-emergency environment, market acceptance and insurance reimbursement for prophylactic antibodies are untested waters ([4]). Will hospitals and insurers support an expensive antibody for prevention, especially as vaccine boosters and oral antivirals abound? There is a risk that uptake will be modest outside of niche use-cases. Additionally, competition could intensify. Major pharmaceutical players have not given up on this space – for example, AstraZeneca has been developing a next-generation long-acting antibody to replace Evusheld ([18]). Pfizer and others might also re-enter if a clear market emerges. Smaller biotechs and academic groups are exploring alternative antibody cocktails or engineered immunoglobulins. Any superior therapies (e.g. a combo that covers more variants, or a longer-lasting injection) could reduce Invivyd’s opportunity. Furthermore, COVID-19 itself is a moving target; if the overall risk perception of the disease continues to decline, fewer individuals (and physicians) may seek monoclonal prophylaxis. These uncertainties around market size make it hard to project long-term revenue. Invivyd’s platform approach aims to tackle other viruses like RSV and measles, but those programs are preclinical – meaning no diversification of revenue in the near term. The company is, for now, highly dependent on COVID-19 for its commercial success. That concentration adds risk, especially if the pandemic continues to evolve in a less severe direction or if public health policy shifts away from monoclonal solutions.
– Financing & Dilution: While Invivyd’s recent capital raises have bolstered its cash reserves, they also highlight a risk: the company’s need for external financing until it reaches sustainable profitability. In 2022–2023, Invivyd’s predecessor burned substantial cash on ADG20 development, and the company had to restructure and cut staff to conserve capital ([3]) ([3]). In 2025, Invivyd issued a large number of shares (over 100 million new shares including warrants) to raise funds ([11]) ([8]). Existing shareholders were significantly diluted – a necessary trade-off to ensure the company’s survival and progress. If PEMGARDA sales or VYD2311 trial results underwhelm, Invivyd might be forced to raise capital again, potentially at unfavorable terms. The company does have the $30M SVB term loan facility as a cushion, but that debt can only be drawn if revenue milestones are met and comes with covenants including required minimum cash levels ([13]). In a downside scenario (e.g., EUA revoked or trial failure), Invivyd could face a cash crunch, and debt markets might not be accessible. Thus far management has done well to finance ahead of need, but future dilution remains an ongoing risk until the business becomes self-funding. Investors should also be aware that if the stock price surges on positive news, the company may opportunistically issue additional shares (at-the-market or secondary offerings) – a common practice for biotech firms. This could cap upside unless matched by fundamental value growth.
– Legal and Governance Issues: A noteworthy overhang is a securities class-action lawsuit filed in 2023 alleging that Adagio/Invivyd and certain former officers misled investors about ADG20’s efficacy against Omicron ([9]). The complaint claims the company made materially false statements in 2021 regarding its antibody’s breadth, which came into question when Omicron emerged. Invivyd is vigorously contesting the case and has moved to dismiss it ([9]). While the outcome is uncertain, such litigation can be costly and distracting. It also underscores past credibility issues – some investors may feel management was overoptimistic or not transparent, which can hurt trust. On the governance front, Invivyd has seen significant turnover in leadership. The original CEO (Tillman Gerngross) resigned in Feb 2022 amid the ADG20 setback ([3]). In late 2022, the CFO and Chief Commercial Officer also departed, and the company cut several commercial roles to refocus on R&D ([3]). Currently, Invivyd does not have a permanent CEO; the Chief Financial Officer, William Duke, is serving as Principal Executive Officer ([19]). While Chairman Marc Elia appears to be actively guiding strategy, the absence of a dedicated CEO could be seen as a red flag. It raises questions about long-term leadership and the ability to attract top talent. On the other hand, the lean C-suite might be temporary as the company transitions from survival mode to growth mode. Investors will want to see if Invivyd firms up its executive team (e.g. appointing a CEO or CCO) as it approaches a potential product launch. Insider ownership and backing is another consideration – the chairman’s venture firm and other insiders hold significant stakes, which aligns interests but could also concentrate decision-making. Any insider selling (e.g., a large holder reducing position) could pressure the stock. Overall, governance risk at Invivyd is moderate, but worth watching given the past upheavals.
In summary, Invivyd’s key risks revolve around the scientific uncertainty of making an effective, lasting COVID antibody and the commercial uncertainty of how, and if, such a product will be broadly adopted. Financial discipline and execution will be critical, as will adaptability to the virus and market. The company faces external challenges (virus mutation, competition) and internal ones (maintaining investor confidence and talent) in its quest to deliver returns.
Open Questions and Outlook
Invivyd presents a compelling story with significant upside, but also unanswered questions that will determine its ultimate success:
– Will VYD2311 prove its worth in Phase 3? The Fast Track designation and Phase 1/2 data (showing a 76-day half-life for IM dosing) ([4]) ([4]) are encouraging, but the real test will be the DECLARATION trial’s outcome. Can a monoclonal antibody meaningfully reduce symptomatic COVID-19 in a broad population (including “ordinary” individuals without severe immune compromise) ([4]) ([4])? If VYD2311 only shows modest efficacy or runs into safety issues, Invivyd’s core thesis could unravel. On the flip side, if results are robust, how quickly can the company move to file a Biologics License Application and ramp up manufacturing? The timeline – mid-2026 data readout – leaves little room for delays if Invivyd hopes to capitalize on its head start.
– What is the true market opportunity for preventive COVID antibodies? This is perhaps the biggest unknown for investors. We know there is a subset of patients (e.g. transplant recipients, cancer patients on therapy, people with immune disorders) who remain at high risk from COVID despite vaccination ([4]). This population likely numbers a few million globally. If VYD2311 is approved, will physicians widely prescribe it to these patients, and will payors cover it? During the pandemic, the U.S. government essentially provided Evusheld to patients at no cost ([14]). In a commercial setting, pricing and reimbursement will be critical. Monoclonals are expensive to produce; will insurers pay, say, tens of thousands of dollars per patient per year for prophylaxis? There’s also the question of broader use: might relatively healthy individuals seek an antibody shot for extra protection during a surge (similar to how some get annual flu antibody shots)? Invivyd is positioning VYD2311 as a “vaccine-alternative” for those who want additional protection ([1]), but public health agencies might prioritize vaccines for the general population. Market education and demand generation will be needed – something Invivyd has started with its own salesforce for PEMGARDA. The company’s addition of PEMGARDA to NCCN guidelines for lymphoma patients is a positive sign of medical community acceptance ([4]). Still, the total addressable market remains a moving target, influenced by COVID’s trajectory and societal attitudes. Investors should watch early utilization trends (if any) and guidance from management on expected uptake.
– How will competition and the virus’ evolution impact Invivyd’s lead? Invivyd is currently in a leading position, with an authorized product and an advanced candidate. However, as noted, AstraZeneca and others are developing next-gen antibodies ([18]). By the time VYD2311 is on the market (possibly in 2027), there could be another prophylactic antibody available or a combo cocktail that offers broader protection. Moreover, mRNA vaccine technology is also evolving (variant-specific boosters, nasal vaccines, etc.) which could reduce the need for passive immunity in all but the most vulnerable. Invivyd may find itself needing to continually innovate – the company’s INVYMAC platform is supposed to enable rapid antibody discovery ([19]), but can it truly keep pace with a mutating virus on an annual cadence? An open question is whether Invivyd will expand its antibody portfolio (e.g. combining two antibodies for more variant coverage, akin to how HIV or cancer therapies use combos). The mention of NVD200 combo in 2022 ([3]) suggests the company considered this, but current trials focus on single agents. If single-antibody prophylaxis proves too vulnerable to escape, Invivyd might need to pivot to combinations or multi-epitope strategies, which could increase development time and costs. In terms of virus evolution: will SARS-CoV-2 eventually hit a fitness plateau such that new variants are only minor tweaks (allowing one antibody to remain effective longer)? Or will it throw a curveball variant that evades all current antibodies in 2026? This unpredictability is a core risk – and it will influence how sustainable Invivyd’s product revenue can be.
– Can Invivyd leverage its platform beyond COVID-19? The company’s long-term vision is to “protect humanity from serious viral diseases” using monoclonal antibodies ([20]). It has initiated early work on targets like RSV (respiratory syncytial virus) and measles ([4]). These represent sizable markets – RSV prophylaxis in infants and elderly is an active field (with newly approved long-acting antibodies from Sanofi/AstraZeneca, and vaccines), and measles outbreaks could be addressed with antibodies for unvaccinated populations. However, Invivyd’s efforts here are preclinical; an RSV candidate identification is expected by Q3 2025 ([4]), which indicates they might have something to announce, but actual clinical trials are presumably years away. There is an open question whether Invivyd will partner or seek non-dilutive funding for these programs (since larger players dominate RSV prophylaxis). The ability to diversify into another virus would greatly strengthen the company’s profile and reduce reliance on COVID cycles. In the next 12–18 months, any concrete progress or collaborations on RSV/measles could be a catalyst. Conversely, if those programs languish, investors may view Invivyd as a one-trick pony. The SPEAR Long COVID study group initiative is another intriguing angle – exploring whether antibodies like PEMGARDA might help long COVID or post-vaccine syndromes ([21]). It’s a very early, investigational idea (no clinical trial yet, just a study group endorsement), so we wouldn’t assign value to it now. But it underscores the flexibility of Invivyd’s platform: antibodies could potentially be used not just for prevention, but for treatment or mitigation of post-viral conditions. It’s an open question whether this will materialize into studies and results.
– What will Invivyd’s financial profile look like in 1–2 years? By late 2026, we should have Phase 3 results for VYD2311 and perhaps even FDA filing status. If positive, Invivyd might be gearing up for commercialization with a larger sales force, inventory build, etc. Expenses will likely rise in preparation for launch, potentially outpacing EUA revenue – meaning the company could dip deeper into its cash reserves. Will the current cash (>$200M) be enough to get through approval and into launch? Or will Invivyd need to raise more capital, perhaps to scale up manufacturing or marketing for VYD2311? The answer depends on how efficiently they run trials and how PEMGARDA revenue contributes in the interim. On the flip side, if VYD2311 falters, what is Plan B for the cash? Does Invivyd pivot to another COVID antibody (essentially restarting the clock), or double down on other viruses? The company’s valuation at that point will hinge on those decisions. Investors should also consider the possibility of M&A: if VYD2311 data are strong, Invivyd could become an acquisition target for a large pharma company looking to bolster its infectious disease portfolio. Alternatively, Invivyd might seek a commercialization partner for ex-U.S. markets to maximize reach. These strategic decisions are yet to be determined – and represent potential upside or downside. For now, management’s focus is on execution: hitting trial milestones, driving PEMGARDA uptake, and managing the cash burn. Their ability to deliver on these fronts over the next year will provide answers to many of today’s open questions.
Bottom line: Invivyd offers a high-risk, high-reward profile. The Fast Track status for VYD2311 is an encouraging signal, and the company’s proactive financing and solid execution (launching a product under EUA and advancing a Phase 3 in short order) deserve credit. However, investors should not lose sight of the uncertainties – regulatory hurdles, variant changes, market dynamics, and financing needs could all dramatically alter the narrative. “Don’t miss out” might be the rallying cry, but prudent analysis means preparing for what could go wrong as well as right. As we head into 2026, all eyes will be on Invivyd’s clinical results and its ability to navigate the post-pandemic landscape. This equity remains a speculative play hinging on scientific and commercial validation that is still on the horizon.
Sources: Key information for this report was obtained from Invivyd’s SEC filings, press releases, and reputable financial media. For instance, the company’s 10-K and 10-Q filings provide details on its dividend policy (no dividends) ([9]), cash position and recent offerings ([8]) ([10]), and the SVB loan terms ([13]). Invivyd’s own press releases were used to document product revenue trends and financial results ([5]) ([7]), as well as pipeline updates like the FDA Fast Track designation for VYD2311 ([1]). Industry articles (e.g., FierceBiotech/FiercePharma) and FDA announcements provided context on management changes ([3]), competitor activity, and the fate of AstraZeneca’s Evusheld ([14]) ([18]). These sources, cited inline, underpin the analysis and help ensure a factual, grounded assessment of Invivyd’s outlook.
Sources
- https://globenewswire.com/news-release/2025/12/23/3209795/0/en/invivyd-earns-fast-track-designation-for-vyd2311-a-vaccine-alternative-antibody-to-prevent-covid.html
- https://globenewswire.com/news-release/2022/09/12/2513854/0/en/Adagio-Therapeutics-Announces-Corporate-Name-Change-to-Invivyd.html
- https://fiercebiotech.com/biotech/invivyd-faces-c-suite-departures-commercial-layoffs-rebranded-adagios-turmoil-continues
- https://investors.invivyd.com/news-releases/news-release-details/invivyd-reports-second-quarter-2025-financial-results-and-recent
- https://investors.invivyd.com/news-releases/news-release-details/invivyd-reports-fourth-quarter-and-full-year-2024-financial/
- https://investors.invivyd.com/news-releases/news-release-details/invivyd-reports-first-quarter-2025-financial-results-and-recent
- https://biospace.com/press-releases/invivyd-reports-third-quarter-2025-financial-results-and-recent-business-highlights
- https://globenewswire.com/news-release/2025/11/06/3182418/0/en/Invivyd-Reports-Third-Quarter-2025-Financial-Results-and-Recent-Business-Highlights.html
- https://sec.gov/Archives/edgar/data/1832038/000095017024037610/ivvd-20231231.htm
- https://globenewswire.com/news-release/2025/11/18/3189659/0/en/Invivyd-Announces-Pricing-of-125-Million-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html
- https://investors.invivyd.com/news-releases/news-release-details/invivyd-announces-pricing-50-million-public-offering-common
- https://investors.invivyd.com/news-releases/news-release-details/invivyd-announces-30m-non-dilutive-loan-facility-silicon-valley/
- https://sec.gov/Archives/edgar/data/1832038/000095017025056005/ivvd-20250418.htm
- https://fiercepharma.com/pharma/astrazeneca-reports-sales-drop-evusheld-whats-underachieving-covid-med
- https://ycharts.com/companies/VIR/market_cap
- https://tipranks.com/stocks/vir/market-cap
- https://investors.invivyd.com/news-releases/news-release-details/invivyd-reports-third-quarter-2024-financial-results-and-recent
- https://managedhealthcareexecutive.com/fda-removes-evusheld-s-eua-for-covid-19
- https://cnbc.com/quotes/IVVD
- https://investors.invivyd.com/news-releases/news-release-details/adagio-therapeutics-announces-corporate-name-change-invivyd
- https://ainvest.com/news/invivyd-nasdaq-ivvd-surges-7-21-fda-fast-track-alignment-spear-study-endorsement-2512/
For informational purposes only; not investment advice.
